Sinisa Radulovic

Summary

Affiliation: Institute for Oncology and Radiology of Serbia
Country: Serbia and Montenegro

Publications

  1. ncbi Trans-platinum complexes as anticancer drugs: recent developments and future prospects
    S Radulovic
    Dept Drug Development, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, 11000, Yugoslavia
    Curr Med Chem 9:1611-8. 2002
  2. ncbi [Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma]
    Sinisa Radulovic
    Institute for Oncology and Radiology of Serbia, Belgrade
    Srp Arh Celok Lek 131:345-50. 2003
  3. ncbi Sunitinib, sorafenib and mTOR inhibitors in renal cancer
    Sinisa Radulovic
    Department of Translational Research, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    J BUON 12:S151-62. 2007
  4. ncbi Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes
    Snezana Bjelogrlić
    Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Laboratory for Experimental Pharmacology, Pasterova 14, Belgrade, Serbia
    J Inorg Biochem 104:673-82. 2010
  5. ncbi A comparative study of DNA binding and cell cycle phase perturbation by the dinuclear complex of Cd(II) with the condensation product of 2-acetylpyridine and malonic acid dihydrazide N',N'(2) -bis[(1E)-1-(2-pyridyl)ethylidene]propanedihydrazide
    Miroslava Vujcic
    Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, Belgrade, Serbia
    J Biochem Mol Toxicol 25:175-82. 2011
  6. ncbi Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway
    Tatjana Srdic-Rajic
    Department of Experimental Oncology, Laboratory for Experimental Pharmacology, Institute for Oncology and Radiology of Serbia, National Cancer Research Center, Pasterova 14, 11 000 Belgrade, Serbia
    Eur J Med Chem 46:3734-47. 2011
  7. ncbi Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure
    Nevenka Gligorijević
    Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    J Inorg Biochem 108:53-61. 2012
  8. ncbi Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives
    Snezana K Bjelogrlic
    Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia
    Curr Pharm Des 14:1058-77. 2008
  9. ncbi Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition
    Jelena Dobricić
    Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    Cancer Genet Cytogenet 202:27-32. 2010
  10. ncbi IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC
    Gordana Konjevic
    Department of Experimental Immunology, Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia
    Clin Exp Metastasis 20:647-55. 2003

Collaborators

  • Dusan Sladic
  • Sanja Grgurić-Sipka
  • Miroslava Vujcic
  • Snezana Susnjar
  • Zvonko Magic
  • Jelena Dobričić
  • Gordana Konjevic
  • Manja Zec
  • Tatjana Srdic-Rajic
  • Tamara Todorović
  • Nevenka Gligorijević
  • Snezana K Bjelogrlic
  • Radmila Janković
  • Ksenija Jakovljević
  • Katarina K Jovanović
  • Snezana Bjelogrlić
  • Katarina Andelković
  • Sladjana Z Spasić
  • Ksenija Radotic
  • Aleksandar G Savić
  • Aleksandra Konic-Ristic
  • Ivana Filipović-Lješković
  • Zivoslav Lj Tesić
  • Milena Cavić
  • Emina Malisic
  • Lana Filipović
  • Ivanka Ivanović
  • Katarina Andjelković
  • Sandra Aranđelović
  • Katarina Anđelković
  • Giancarlo Pelizzi
  • Dusanka Radanović
  • Alessia Bacchi
  • Dejan Jeremić
  • Nenad Filipovic
  • Dejan Godevac
  • Nada Babovic
  • Milan Jokanovic
  • Jelena Radic
  • Viktor Jovic

Detail Information

Publications17

  1. ncbi Trans-platinum complexes as anticancer drugs: recent developments and future prospects
    S Radulovic
    Dept Drug Development, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, 11000, Yugoslavia
    Curr Med Chem 9:1611-8. 2002
    ..Trans-platinum compounds, appear to follow different pattern of cell killing in comparison to cisplatin, thus giving a reason for optimism in their development as a new class of platinum-based antitumor drugs...
  2. ncbi [Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma]
    Sinisa Radulovic
    Institute for Oncology and Radiology of Serbia, Belgrade
    Srp Arh Celok Lek 131:345-50. 2003
    ..Genetic testing, which plays a role in defining risk, requires careful pre- and post-test counseling to discuss the limitations of testing itself and available management strategies...
  3. ncbi Sunitinib, sorafenib and mTOR inhibitors in renal cancer
    Sinisa Radulovic
    Department of Translational Research, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    J BUON 12:S151-62. 2007
    ..The development of these targeted therapies represents an exciting step forward in the treatment of advanced RCC...
  4. ncbi Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes
    Snezana Bjelogrlić
    Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Laboratory for Experimental Pharmacology, Pasterova 14, Belgrade, Serbia
    J Inorg Biochem 104:673-82. 2010
    ....
  5. ncbi A comparative study of DNA binding and cell cycle phase perturbation by the dinuclear complex of Cd(II) with the condensation product of 2-acetylpyridine and malonic acid dihydrazide N',N'(2) -bis[(1E)-1-(2-pyridyl)ethylidene]propanedihydrazide
    Miroslava Vujcic
    Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, Belgrade, Serbia
    J Biochem Mol Toxicol 25:175-82. 2011
    ..Immunoblotting analysis showed the overexpression of Bcl-2 protein with the Cd(II)H(2) L complex...
  6. ncbi Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway
    Tatjana Srdic-Rajic
    Department of Experimental Oncology, Laboratory for Experimental Pharmacology, Institute for Oncology and Radiology of Serbia, National Cancer Research Center, Pasterova 14, 11 000 Belgrade, Serbia
    Eur J Med Chem 46:3734-47. 2011
    ....
  7. ncbi Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure
    Nevenka Gligorijević
    Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    J Inorg Biochem 108:53-61. 2012
    ....
  8. ncbi Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives
    Snezana K Bjelogrlic
    Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia
    Curr Pharm Des 14:1058-77. 2008
    ..This article overviews current knowledge in RCC molecular pathology with recent clinical data, and discuss present strategies for future development of targeted therapies...
  9. ncbi Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition
    Jelena Dobricić
    Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    Cancer Genet Cytogenet 202:27-32. 2010
    ..Steroid receptor-positive BRCA-related breast cancer in this proband supports the idea of characteristic pathological features and older age of onset among BRCA1-mutated ER-positive breast cancers...
  10. ncbi IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC
    Gordana Konjevic
    Department of Experimental Immunology, Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia
    Clin Exp Metastasis 20:647-55. 2003
    ....
  11. ncbi Association between methylenetetrahydrofolate reductase polymorphism C677T and risk of chronic myeloid leukemia in Serbian population
    Ksenija Jakovljević
    Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    Leuk Lymphoma 53:1327-30. 2012
    ..Our findings suggest that MTHFR 677 gene variants have no significant influence on the susceptibility to CML in a Serbian population...
  12. ncbi Anti-metastatic and anti-angiogenic properties of potential new anti-cancer drugs based on metal complexes of selenosemicarbazones
    Manja Zec
    National Cancer Research Center, Department of Experimental Pharmacology, Serbia
    Anticancer Agents Med Chem 12:1071-80. 2012
    ..In addition, they could modulate metastatic phenotype of tumor cells. Nickel (II) complex with 2-formylpyridine selenosemicarbazone revealed to be the most potent...
  13. ncbi Synthesis and characterization of new Pt(II) and Pd(II) complexes with 2-quinolinecarboxaldehyde selenosemicarbazone: cytotoxic activity evaluation of Cd(II), Zn(II), Ni(II), Pt(II) and Pd(II) complexes with heteroaromatic selenosemicarbazones
    Nevenka Gligorijević
    Laboratory for Experimental Pharmacology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia
    Eur J Med Chem 44:1623-9. 2009
    ..The investigation of potential of these compounds to induce HeLa cell cycle perturbations was also evaluated...
  14. ncbi Detection of DNA mutations based on analysis of multiple wavelength excitation/emission fluorescence kinetics curves in real-time PCR
    Katarina K Jovanović
    Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Pasterova 14, Belgrade, Serbia
    Med Hypotheses 80:376-9. 2013
    ..Method can be applied to any kit, capable to simultaneously detect several different mutations...
  15. ncbi Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients
    Snezana Susnjar
    Department for Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia
    Support Care Cancer 16:1415-8. 2008
    ..DISCUSSION: We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel...
  16. ncbi Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo
    Snezana K Bjelogrlic
    Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia
    Exp Biol Med (Maywood) 232:1414-24. 2007
    ..Dexrazoxane has proved to be successful and superior over amifostine against such an evolution of doxorubicin cardiomyopathy...
  17. ncbi cDNA microarrays: identification of gene signatures and their application in clinical practice
    Zvonko Magic
    Institute for Medical Research, Military Medical Academy, Belgrade, Serbia
    J BUON 12:S39-44. 2007
    ..Gene expression profiles will also help clinicians make decisions about the optimal treatment of cancer patients...